First National Bank of Omaha’s Harmony Biosciences HRMY Stock Holding History

First National Bank of Omaha’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,547	Closed	-$301K	–	326
2023 Q2	$301K	Hold	8,547	–	–	0.02%	302
2023 Q1	$279K	Buy	8,547 +2,818	+49%	+$128K	0.02%	304
2022 Q4	$316K	Buy	+5,729	New	+$315K	0.02%	297

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

First National Bank of Omaha's HRMY Position: Q3 2023 in Review

First National Bank of Omaha sold out of Harmony Biosciences (HRMY) in Q3 2023, closing a stake of 8,547 shares — an estimated $301K sold.

First National Bank of Omaha first reported a position in HRMY in Q4 2022 and held it in 3 quarters. The position peaked at $316K in Q4 2022. 204 funds tracked by Wall St. Rank hold HRMY as of Q3 2023.

First National Bank of Omaha reported no remaining Harmony Biosciences position as of Q3 2023 after selling out during the quarter.
First National Bank of Omaha sold 8,547 Harmony Biosciences shares in Q3 2023, an estimated $301K.
First National Bank of Omaha first reported a position in Harmony Biosciences in Q4 2022 and held it in 3 quarters.
First National Bank of Omaha's Harmony Biosciences position peaked at $316K in Q4 2022.
204 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2023.

Based on First National Bank of Omaha's 13F filing for Q3 2023, filed 14 Nov 2023.